Elestat

(Epinastine)

Phase 3Small molecule

VVitae Pharmaceuticals Inc., an Allergan affiliate

Elestat is one of 56 small molecule programs targeting Allergic Rhinitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Allergic RhinitisActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Allergic RhinitisPhase 3

Active, not recruiting

Seasonal Allergic RhinitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Asmanex Hfa

PPerrigo Company

Phase 3

5 2

Sudafed

KKenvue Brands

Phase 3

3 3

Flovent

PParatek Pharmaceuticals Inc

Phase 3

2 4

Kenalog

BBassett Healthcare

Phase 3

1 5

Rayos

RRoxane Laboratories

Phase 3

1 6

Active Comparator

Moderna

Phase 3

1 7

Immunotherapy

Bristol-Myers Squibb

Phase 3

1 8

Elestat

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 9

Allegra-D

Pfizer

Phase 3

3 10

Asmanex

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPA2 trials

Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02182531·25 enrolled

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02260063·24 enrolled

Allergic Rhinitis1 trial

Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02182518·101 enrolled

Tolerance1 trial

Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02260037·39 enrolled

Seasonal Allergic Rhinitis1 trial

A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00407927·571 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 16, 2003

ELESTAT

NDA NDA021565

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Epinastine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Epinastine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Epinastine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA021565). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Vitae Pharmaceuticals Inc., an Allergan affiliate company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVitae Pharmaceuticals Inc., an Allergan affiliate

Elestat

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPA2 trials

Allergic Rhinitis1 trial

Tolerance1 trial

Seasonal Allergic Rhinitis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News